Authors' Reply to Curto and Garattini: 'Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers'

摘要

Dear Editor, We thank Dr. Garattini and Mr. Curto for their comments and will gladly provide further clarification [1]. The original article from which the taxonomy used in our current article was taken focused on health outcomes arrangements and excluded non-outcomes-based schemes [2, 3]. Therefore, the original article includes definitions for coverage with evidence development (CED), conditional treatment continuation (CTC), and performance-linked reimbursement (PLR) categories but not financial/utilization (FU). The FU category is represented by the non-outcomes schemes, which are included in the taxonomy figure, but not explicitly defined in the figure or in the text. We apologize if this caused some confusion. We define the FU category as arrangements where the reimbursement is tied to the measure of financial or utilization outcomes as opposed to explicit clinical outcomes.